FDA grants traditional approval to Novartis’ Fabhalta for IgAN
Pharmaceutical Business Review
This first-in-class complement inhibitor received the approval through a priority review process after its initial accelerated approval in August 2024 for reducing proteinuria in primary IgAN.
pharminent
July 17, 2026 (Last updated: July 27, 2026)
Pharmaceutical Business Review
This first-in-class complement inhibitor received the approval through a priority review process after its initial accelerated approval in August 2024 for reducing proteinuria in primary IgAN.